S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02913066

Recruitment Status : Unknown

Verified June 2017 by Xiaobo Du, Mianyang Central Hospital.
Recruitment status was: Recruiting

First Posted : September 23, 2016

Last Update Posted : June 16, 2017

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Xiaobo Du, Mianyang Central Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	March 2019
Estimated Study Completion Date :	March 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhao Z, Wen Y, Liao D, Miao J, Gui Y, Cai H, Chen Y, Wei M, Jia Q, Tian H, Sun M, Zhang Y, Feng G, Du X. Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial. Oncologist. 2020 Dec;25(12):e1900-e1908. doi: 10.1634/theoncologist.2020-0808. Epub 2020 Sep 28.

To Top